19
Participants
Start Date
April 30, 2012
Primary Completion Date
February 28, 2014
Study Completion Date
October 31, 2014
Iloperidone
Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
Northwestern University, Chicago
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Northwestern University
OTHER